Lanxess Faces Analyst Scrutiny Ahead of Quarterly Report

Ahead of its first-quarter earnings release, specialty chemicals company Lanxess finds itself under a cloud of analyst skepticism. Three major financial institutions have recently issued cautious assessments, setting the stage for a critical test of market sentiment.

Revised Targets and Cautious Stances

The consensus among market experts is notably restrained. Barclays has taken the most bearish position, assigning an "Underweight" rating and setting a price target of €11.50. Jefferies maintains a "Hold" recommendation with a €17 target, anticipating weak dynamics for Q1 and only a potential slight improvement from the second quarter onward.

In a significant move, Goldman Sachs has reduced its price objective for Lanxess from €23 to €21, while keeping a "Neutral" rating. This adjustment stems from the firm's own EBITDA estimates, which sit approximately 11% below the broader market consensus. This gap indicates Goldman Sachs holds a more pessimistic view of the company's near-term operational earnings power than most of its peers.

Should investors sell immediately? Or is it worth buying Lanxess?

Technical and Fundamental Headwinds

Despite the stock recently breaking above its 50-day moving average near €17.30, significant technical and fundamental challenges remain. The long-term 200-day line, positioned around €20, is still distant, representing an 11% gap. Furthermore, with a Relative Strength Index (RSI) reading of 71.3, the short-term recovery is technically considered extended.

The analyst caution extends beyond quarterly performance concerns. The entire chemical sector is grappling with pressures from geopolitical tensions, which disrupt energy supplies and logistics. Lanxess is viewed as particularly exposed to upstream raw material markets, where ongoing price volatility continues to structurally compress margins.

The company's balance sheet adds another layer of scrutiny, showing a debt ratio of 72.47. This has kept the stock on the radar of short-sellers.

The upcoming Q1 results will serve as a key indicator, revealing whether Goldman Sachs's below-consensus EBITDA forecast was accurate or if Lanxess can deliver a positive surprise to the market.

Ad

Lanxess Stock: New Analysis - 5 April

Fresh Lanxess information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Lanxess analysis...

DE0005470405 | LANXESS | boerse | 69076781 |